Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Generic Paxil CR Will Launch By October 2008 Under GSK/Mylan Settlement

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Mylan gains rights to market extended-release paroxetine in 12.5 mg, 25 mg and 37.5 mg doses.

You may also be interested in...



Mylan Launches Generic Paxil CR

Launch includes 180-day exclusivity for 12.5 mg and 25 mg paroxetine tablets, and follows patent settlement with GSK last year.

Mylan Launches Generic Paxil CR

Launch includes 180-day exclusivity for 12.5 mg and 25 mg paroxetine tablets, and follows patent settlement with GSK last year.

Generic Keppra Set For Launch In November 2008 After UCB Settles

Mylan could launch generic versions of the antiepileptic Nov. 1, 2008, two months ahead of anticipated exclusivity expiry of levetiracetam.

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By